AAPGNasdaqPharmaceutical PreparationsFiscal year ends December 31

ASCENTAGE PHARMA GROUP INTERNATIONAL

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026

$15.36−0.01 (-0.07%)

Close on Oct 19, 2026

Debt

Borrowings on the balance sheet, Dec 31, 2025

Total debt

CN¥1.99B

CN¥1.23B due within a year

Net debt

CN¥792.28M

After CN¥1.20B of cash

Implied interest rate

2.93%

FY2025 interest ÷ average debt

Interest coverage

–

FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, CNY

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Ascentage Pharma Group International's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Ascentage Pharma Group International's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AAPG.

Revenue growth-41.5% · median 54.9%

Gross margin91.5% · median 70.3%

Net margin-216.5% · median -64.3%

Company	Revenue	Growth
LEGN	$1.27B	+59.5%
INSM	$1.14B	+185.8%
RARE	$717.21M	+17.5%
AAPG	CN¥574.12M	-41.5%
LGND	$290.54M	+54.9%
HCM	$204.89M	-4.3%

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 767
Held by institutions: 0.0%
Auditor: Ernst & Young Hua Ming LLP
SEC CIK: 2023311

Advertisement
300 × 250